XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreement (Details)
$ in Millions
3 Months Ended
Mar. 22, 2022
USD ($)
payment
shares
Mar. 31, 2023
shares
Dec. 31, 2022
shares
License Agreement      
Series A-1 convertible preferred shares authorized | shares   0 13,510,415
Agreement with Pfizer      
License Agreement      
Amount of cash transferred $ 5.0    
Number of shares transferred | shares 2,702,083    
Percentage of interest 20.00%    
Value allocated to in-process research and development $ 7.5    
Number of development and regulatory milestone payments | payment 12    
Maximum amount of development and regulatory milestone payments $ 70.0    
Maximum amount of sales milestone payments $ 525.0    
Maximum annual earned royalty at a marginal royalty rate 20.00%    
Percentage of anti-dilution provisions to be maintained   18.00%  
Series A-1 convertible preferred shares authorized | shares   267,939